Reuters logo
BRIEF-Antisense Therapeutics says FDA lifts hold for multiple sclerosis drug study
October 1, 2017 / 11:13 PM / in 16 days

BRIEF-Antisense Therapeutics says FDA lifts hold for multiple sclerosis drug study

Oct 2 (Reuters) - Antisense Therapeutics Ltd:

* Advised by FDA that full clinical hold for phase IIb clinical study of ATL1102 for multiple sclerosis has been lifted

* Co’s application to conduct clinical trial of ATL1102 has been approved by Human Research Ethics Committee Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below